- Home
- Publications
- Publication Search
- Publication Details
Title
Antisense Oligonucleotide-Based Therapy for Neuromuscular Disease
Authors
Keywords
-
Journal
MOLECULES
Volume 22, Issue 4, Pages 563
Publisher
MDPI AG
Online
2017-04-05
DOI
10.3390/molecules22040563
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Safety, tolerability, and antiviral effect of RG-101 in patients with chronic hepatitis C: a phase 1B, double-blind, randomised controlled trial
- (2017) Meike H van der Ree et al. LANCET
- Lipid-based nanocarriers for oral peptide delivery
- (2016) Zhigao Niu et al. ADVANCED DRUG DELIVERY REVIEWS
- The role of helper lipids in lipid nanoparticles (LNPs) designed for oligonucleotide delivery
- (2016) Xinwei Cheng et al. ADVANCED DRUG DELIVERY REVIEWS
- Peptides for nucleic acid delivery
- (2016) Taavi Lehto et al. ADVANCED DRUG DELIVERY REVIEWS
- Vascular Defects and Spinal Cord Hypoxia in Spinal Muscular Atrophy
- (2016) Eilidh Somers et al. ANNALS OF NEUROLOGY
- Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy
- (2016) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Therapeutic nucleic acids: current clinical status
- (2016) Kannan Sridharan et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Antisense targeting of 3′ end elements involved inDUX4mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach
- (2016) Anne-Charlotte Marsollier et al. HUMAN MOLECULAR GENETICS
- Antisense molecules: A new class of drugs
- (2016) Daniel P. Potaczek et al. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY
- Stakeholder cooperation to overcome challenges in orphan medicine development: the example of Duchenne muscular dystrophy
- (2016) Volker Straub et al. LANCET NEUROLOGY
- Morpholino-mediated Knockdown of DUX4 Toward Facioscapulohumeral Muscular Dystrophy Therapeutics
- (2016) Jennifer CJ Chen et al. MOLECULAR THERAPY
- Biological interactions of carbon-based nanomaterials: From coronation to degradation
- (2016) Kunal Bhattacharya et al. Nanomedicine-Nanotechnology Biology and Medicine
- Results from a phase 1 study of nusinersen (ISIS-SMNRx) in children with spinal muscular atrophy
- (2016) Claudia A. Chiriboga et al. NEUROLOGY
- The delivery of therapeutic oligonucleotides
- (2016) Rudolph L. Juliano NUCLEIC ACIDS RESEARCH
- Histopathological Defects in Intestine in Severe Spinal Muscular Atrophy Mice Are Improved by Systemic Antisense Oligonucleotide Treatment
- (2016) Palittiya Sintusek et al. PLoS One
- Systemic peptide-mediated oligonucleotide therapy improves long-term survival in spinal muscular atrophy
- (2016) Suzan M. Hammond et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Altered Levels of MicroRNA-9, -206, and -132 in Spinal Muscular Atrophy and Their Response to Antisense Oligonucleotide Therapy
- (2016) Francesco Catapano et al. Molecular Therapy-Nucleic Acids
- Long-Term Efficacy, Safety, and Pharmacokinetics of Drisapersen in Duchenne Muscular Dystrophy: Results from an Open-Label Extension Study
- (2016) Nathalie M. Goemans et al. PLoS One
- Severe impairment of male reproductive organ development in a low SMN expressing mouse model of spinal muscular atrophy
- (2016) Eric W. Ottesen et al. Scientific Reports
- Survival Motor Neuron (SMN) protein is required for normal mouse liver development
- (2016) Eva Szunyogova et al. Scientific Reports
- Cellular uptake and intracellular trafficking of oligonucleotides
- (2015) R.L. Juliano et al. ADVANCED DRUG DELIVERY REVIEWS
- Bioconjugates for targeted delivery of therapeutic oligonucleotides
- (2015) Xin Ming et al. ADVANCED DRUG DELIVERY REVIEWS
- Delivery of therapeutic oligonucleotides with cell penetrating peptides
- (2015) Prisca Boisguérin et al. ADVANCED DRUG DELIVERY REVIEWS
- Antisense oligonucleotides in therapy for neurodegenerative disorders
- (2015) Melvin M. Evers et al. ADVANCED DRUG DELIVERY REVIEWS
- Nucleic Acids Delivery Systems: A Challenge for Pharmaceutical Technologists
- (2015) Ana Silva et al. CURRENT DRUG METABOLISM
- Therapeutic Approaches for Dominant Muscle Diseases: Highlight on Myotonic Dystrophy
- (2015) A. Klein et al. CURRENT GENE THERAPY
- An update on RNA-targeting therapies for neuromuscular disorders
- (2015) Silvana Jirka et al. CURRENT OPINION IN NEUROLOGY
- An overview of the clinical application of antisense oligonucleotides for RNA-targeting therapies
- (2015) Graham McClorey et al. CURRENT OPINION IN PHARMACOLOGY
- Animal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapy
- (2015) J. W. McGreevy et al. Disease Models & Mechanisms
- Oligonucleotide Therapies: The Past and the Present
- (2015) Karin E. Lundin et al. HUMAN GENE THERAPY
- Repeated low doses of morpholino antisense oligomer: an intermediate mouse model of spinal muscular atrophy to explore the window of therapeutic response
- (2015) Haiyan Zhou et al. HUMAN MOLECULAR GENETICS
- Low levels of Survival Motor Neuron protein are sufficient for normal muscle function in the SMNΔ7 mouse model of SMA
- (2015) Chitra C. Iyer et al. HUMAN MOLECULAR GENETICS
- Cationic polyelectrolyte-mediated delivery of antisense morpholino oligonucleotides for exon-skipping in vitro and in mdx mice
- (2015) Mingxing Wang et al. International Journal of Nanomedicine
- Gene therapy returns to centre stage
- (2015) Luigi Naldini NATURE
- SMN2 splice modulators enhance U1–pre-mRNA association and rescue SMA mice
- (2015) James Palacino et al. Nature Chemical Biology
- Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomers
- (2015) Aurélie Goyenvalle et al. NATURE MEDICINE
- Cell-penetrating peptides transport therapeutics into cells
- (2015) Joshua D. Ramsey et al. PHARMACOLOGY & THERAPEUTICS
- Systemic, postsymptomatic antisense oligonucleotide rescues motor unit maturation delay in a new mouse model for type II/III spinal muscular atrophy
- (2015) Laurent P. Bogdanik et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Properties of Protein Drug Target Classes
- (2015) Simon C. Bull et al. PLoS One
- Effect of Combined Systemic and Local Morpholino Treatment on the Spinal Muscular Atrophy Δ7 Mouse Model Phenotype
- (2014) Monica Nizzardo et al. CLINICAL THERAPEUTICS
- Oligonucleotide delivery: a patent review (2010 – 2013)
- (2014) Santiago Grijalvo et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- Morpholino antisense oligonucleotides targeting intronic repressor Element1 improve phenotype in SMA mouse models
- (2014) Erkan Y. Osman et al. HUMAN MOLECULAR GENETICS
- Requirement of enhanced Survival Motoneuron protein imposed during neuromuscular junction maturation
- (2014) Shingo Kariya et al. JOURNAL OF CLINICAL INVESTIGATION
- Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study
- (2014) Thomas Voit et al. LANCET NEUROLOGY
- Facioscapulohumeral Muscular Dystrophy
- (2014) Jeffrey Statland et al. NEUROLOGIC CLINICS
- The new frontier of genome engineering with CRISPR-Cas9
- (2014) J. A. Doudna et al. SCIENCE
- SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
- (2014) N. A. Naryshkin et al. SCIENCE
- Molecular Structure, Function, and Dynamics of Clathrin-Mediated Membrane Traffic
- (2014) T. Kirchhausen et al. Cold Spring Harbor Perspectives in Biology
- Nanoparticle Delivery of Antisense Oligonucleotides and Their Application in the Exon Skipping Strategy for Duchenne Muscular Dystrophy
- (2014) Maria Sofia Falzarano et al. Nucleic Acid Therapeutics
- Eteplirsen for the treatment of Duchenne muscular dystrophy
- (2013) Jerry R. Mendell et al. ANNALS OF NEUROLOGY
- Muscular dystrophy
- (2013) Eugenio Mercuri et al. CURRENT OPINION IN PEDIATRICS
- Histone deacetylase inhibitors as potential treatment for spinal muscular atrophy
- (2013) Jafar Mohseni et al. GENETICS AND MOLECULAR BIOLOGY
- A Novel Morpholino Oligomer Targeting ISS-N1 Improves Rescue of Severe Spinal Muscular Atrophy Transgenic Mice
- (2013) Haiyan Zhou et al. HUMAN GENE THERAPY
- Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease?
- (2013) Monir Shababi et al. JOURNAL OF ANATOMY
- Morpholino Treatment Improves Muscle Function and Pathology of Pitx1 Transgenic Mice
- (2013) Sachchida Nand Pandey et al. MOLECULAR THERAPY
- An intronic structure enabled by a long-distance interaction serves as a novel target for splicing correction in spinal muscular atrophy
- (2013) Natalia N. Singh et al. NUCLEIC ACIDS RESEARCH
- Improved Antisense Oligonucleotide Design to Suppress Aberrant SMN2 Gene Transcript Processing: Towards a Treatment for Spinal Muscular Atrophy
- (2013) Chalermchai Mitrpant et al. PLoS One
- Biodistribution and Molecular Studies on Orally Administered Nanoparticle-AON Complexes Encapsulated with Alginate Aiming at Inducing Dystrophin Rescue inmdxMice
- (2013) Maria Sofia Falzarano et al. Biomed Research International
- Design and Analysis of Effects of Triplet Repeat Oligonucleotides in Cell Models for Myotonic Dystrophy
- (2013) Anchel González-Barriga et al. Molecular Therapy-Nucleic Acids
- Persistent Dystrophin Protein Restoration 90 Days after a Course of Intraperitoneally Administered Naked 2′OMePS AON and ZM2 NP-AON Complexes in mdx Mice
- (2012) Elena Bassi et al. JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY
- Motor Neuron Rescue in Spinal Muscular Atrophy Mice Demonstrates That Sensory-Motor Defects Are a Consequence, Not a Cause, of Motor Neuron Dysfunction
- (2012) R. G. Gogliotti et al. JOURNAL OF NEUROSCIENCE
- Targeting nuclear RNA for in vivo correction of myotonic dystrophy
- (2012) Thurman M. Wheeler et al. NATURE
- Genetic Correction of Human Induced Pluripotent Stem Cells from Patients with Spinal Muscular Atrophy
- (2012) S. Corti et al. Science Translational Medicine
- Spinal muscular atrophy: going beyond the motor neuron
- (2012) Gillian Hamilton et al. TRENDS IN MOLECULAR MEDICINE
- Pip6-PMO, A New Generation of Peptide-oligonucleotide Conjugates With Improved Cardiac Exon Skipping Activity for DMD Treatment
- (2012) Corinne Betts et al. Molecular Therapy-Nucleic Acids
- Identification of a Maleimide-Based Glycogen Synthase Kinase-3 (GSK-3) Inhibitor, BIP-135, That Prolongs the Median Survival Time of Δ7 SMA KO Mouse Model of Spinal Muscular Atrophy
- (2011) Po C. Chen et al. ACS Chemical Neuroscience
- Arginine-rich cell-penetrating peptide dramatically enhances AMO-mediated ATM aberrant splicing correction and enables delivery to brain and cerebellum
- (2011) Liutao Du et al. HUMAN MOLECULAR GENETICS
- A single administration of morpholino antisense oligomer rescues spinal muscular atrophy in mouse
- (2011) Paul N. Porensky et al. HUMAN MOLECULAR GENETICS
- Repeat-Dose Toxicology Evaluation in Cynomolgus Monkeys of AVI-4658, a Phosphorodiamidate Morpholino Oligomer (PMO) Drug for the Treatment of Duchenne Muscular Dystrophy
- (2011) Peter Sazani et al. INTERNATIONAL JOURNAL OF TOXICOLOGY
- Exon skipping and dystrophin restoration in patients with Duchenne muscular dystrophy after systemic phosphorodiamidate morpholino oligomer treatment: an open-label, phase 2, dose-escalation study
- (2011) Sebahattin Cirak et al. LANCET
- Pip5 Transduction Peptides Direct High Efficiency Oligonucleotide-mediated Dystrophin Exon Skipping in Heart and Phenotypic Correction in mdx Mice
- (2011) HaiFang Yin et al. MOLECULAR THERAPY
- Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model
- (2011) Yimin Hua et al. NATURE
- Density, calibre and ramification of muscle capillaries are altered in a mouse model of severe spinal muscular atrophy
- (2011) E. Somers et al. NEUROMUSCULAR DISORDERS
- Systemic Administration of PRO051 in Duchenne's Muscular Dystrophy
- (2011) Nathalie M. Goemans et al. NEW ENGLAND JOURNAL OF MEDICINE
- Design principles for bifunctional targeted oligonucleotide enhancers of splicing
- (2011) N. Owen et al. NUCLEIC ACIDS RESEARCH
- Antisense Oligonucleotides Delivered to the Mouse CNS Ameliorate Symptoms of Severe Spinal Muscular Atrophy
- (2011) M. A. Passini et al. Science Translational Medicine
- Facioscapulohumeral muscular dystrophy and DUX4: breaking the silence
- (2011) Silvère M. van der Maarel et al. TRENDS IN MOLECULAR MEDICINE
- RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform
- (2010) C. Frank Bennett et al. Annual Review of Pharmacology and Toxicology
- Antisense correction of SMN2 splicing in the CNS rescues necrosis in a type III SMA mouse model
- (2010) Y. Hua et al. GENES & DEVELOPMENT
- Intravenous scAAV9 delivery of a codon-optimized SMN1 sequence rescues SMA mice
- (2010) Elisa Dominguez et al. HUMAN MOLECULAR GENETICS
- CNS-targeted gene therapy improves survival and motor function in a mouse model of spinal muscular atrophy
- (2010) Marco A. Passini et al. JOURNAL OF CLINICAL INVESTIGATION
- Rescue of the spinal muscular atrophy phenotype in a mouse model by early postnatal delivery of SMN
- (2010) Kevin D Foust et al. NATURE BIOTECHNOLOGY
- Systemic Delivery of scAAV9 Expressing SMN Prolongs Survival in a Model of Spinal Muscular Atrophy
- (2010) C. F. Valori et al. Science Translational Medicine
- Nonviral Gene Delivery: Principle, Limitations, and Recent Progress
- (2009) Mohammed S. Al-Dosari et al. AAPS Journal
- Embryonic stem cell-derived neural stem cells improve spinal muscular atrophy phenotype in mice
- (2009) Stefania Corti et al. BRAIN
- Dose-dependent restoration of dystrophin expression in cardiac muscle of dystrophic mice by systemically delivered morpholino
- (2009) B Wu et al. GENE THERAPY
- Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP–AON complexes
- (2009) A Ferlini et al. GENE THERAPY
- Delivery of bifunctional RNAs that target an intronic repressor and increase SMN levels in an animal model of spinal muscular atrophy
- (2009) T. D. Baughan et al. HUMAN MOLECULAR GENETICS
- Oligonucleotide-Mediated Survival of Motor Neuron Protein Expression in CNS Improves Phenotype in a Mouse Model of Spinal Muscular Atrophy
- (2009) J. H. Williams et al. JOURNAL OF NEUROSCIENCE
- Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study
- (2009) Maria Kinali et al. LANCET NEUROLOGY
- Cationic PMMA Nanoparticles Bind and Deliver Antisense Oligoribonucleotides Allowing Restoration of Dystrophin Expression in the mdx Mouse
- (2009) Paola Rimessi et al. MOLECULAR THERAPY
- Triplet-repeat oligonucleotide-mediated reversal of RNA toxicity in myotonic dystrophy
- (2009) S. A. M. Mulders et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Reversal of RNA Dominance by Displacement of Protein Sequestered on Triplet Repeat RNA
- (2009) T. M. Wheeler et al. SCIENCE
- Antisense Masking of an hnRNP A1/A2 Intronic Splicing Silencer Corrects SMN2 Splicing in Transgenic Mice
- (2008) Yimin Hua et al. AMERICAN JOURNAL OF HUMAN GENETICS
- Improved cell-penetrating peptide–PNA conjugates for splicing redirection in HeLa cells and exon skipping in mdx mouse muscle
- (2008) Gabriela D. Ivanova et al. NUCLEIC ACIDS RESEARCH
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now